Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
The first CD3 antibody to receive approval was Muromonab-CD3; this was followed by the approval of Removab (Catumaxomab). However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market. Newer CD3 antibodies that entered the market after these had various modifications and were based on different technological platforms, which enabled them to avoid the same fate as their predecessors. As a result, there are nine antibodies, which have regulatory approvals from the FDA and EMA.
Among these nine, Blincyto (CD19 Ч CD3) was the first to receive approval; it was approved in 2014 and entered the market in 2015, which allowed it to have a head start in the global CD3 antibodies market in terms of commercial performance. Sales of Blincyto have been increasing year because of its increasing uptake, which has been attributed to the drug being one of the most effective immunotherapies for acute lymphoblastic leukemia. Blincyto collected revenue of US$ 583 million in the year 2022, and in the first half of 2023, the drug has already generated a revenue of US$ 400 million, making it a dominating player in the global CD3 antibodies market.
It is also important to mention that the remaining eight CD3 antibodies were all approved in the years 2022 and 2023, and are only approved in limited regions, which has been disadvantageous for their sales and their share in the global CD3 antibodies market. All these were approved under the FDA’s accelerated approval program and the EMA’s conditional marketing approval program, and their continued approvals are awaited. Nevertheless, their developers are seeking approvals in other regions, which will help them generate more revenues in the market, potentially giving competition to Blincyto’s stance in the global market.
In terms of the clinical development of CD3 antibodies, different cancer indications are dominating. The approved CD3 antibodies have been approved to treat multiple myeloma, lymphoma, uveal melanoma and leukemia, and the same trend is being seen for CD3 antibody candidates in development. Moreover, a majority of these candidates are being developed as bispecific antibodies - T cell engagers to be precise - following a similar mechanism of action as Blincyto and other CD3 antibodies approved for use in cancer. Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are some pharmaceutical companies that have CD3 bispecific T cell engagers in development.
Based on current commercial trends, the market for CD3 antibodies appears to be thriving, with various factors favorably influencing the market. Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market. Another factor is the involvement of important pharmaceutical corporations, which boosts the likelihood of success and financial returns associated with top CD3 antibodies. The invention and use of proprietary platforms, which enabled the development of unique CD3 T cell engagers, allowed developers to construct novel antibodies for rare indications, which came with regulatory benefits such as orphan drug designation. Overall, the global CD3 antibody market has enormous potential, much of which is yet relatively untapped.
Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
- Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028
- Global & Regional Market Trends Analysis
- Current Market Trends, Developments & Clinical Trials Assessment
- CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
- Clinical Insight On 250 CD3 Antibodies In Clinical Trials
- Dosage, Patent, Pricing & Sales Insight on Approved Antibodies
- Clinical Insight On 9 Commercially Approved CD3 Antibodies
- Clinical Trials, Dosage, Price & Sales Analysis Representations In 100 Graphs & Tables
The first CD3 antibody to receive approval was Muromonab-CD3; this was followed by the approval of Removab (Catumaxomab). However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market. Newer CD3 antibodies that entered the market after these had various modifications and were based on different technological platforms, which enabled them to avoid the same fate as their predecessors. As a result, there are nine antibodies, which have regulatory approvals from the FDA and EMA.
Among these nine, Blincyto (CD19 Ч CD3) was the first to receive approval; it was approved in 2014 and entered the market in 2015, which allowed it to have a head start in the global CD3 antibodies market in terms of commercial performance. Sales of Blincyto have been increasing year because of its increasing uptake, which has been attributed to the drug being one of the most effective immunotherapies for acute lymphoblastic leukemia. Blincyto collected revenue of US$ 583 million in the year 2022, and in the first half of 2023, the drug has already generated a revenue of US$ 400 million, making it a dominating player in the global CD3 antibodies market.
It is also important to mention that the remaining eight CD3 antibodies were all approved in the years 2022 and 2023, and are only approved in limited regions, which has been disadvantageous for their sales and their share in the global CD3 antibodies market. All these were approved under the FDA’s accelerated approval program and the EMA’s conditional marketing approval program, and their continued approvals are awaited. Nevertheless, their developers are seeking approvals in other regions, which will help them generate more revenues in the market, potentially giving competition to Blincyto’s stance in the global market.
In terms of the clinical development of CD3 antibodies, different cancer indications are dominating. The approved CD3 antibodies have been approved to treat multiple myeloma, lymphoma, uveal melanoma and leukemia, and the same trend is being seen for CD3 antibody candidates in development. Moreover, a majority of these candidates are being developed as bispecific antibodies - T cell engagers to be precise - following a similar mechanism of action as Blincyto and other CD3 antibodies approved for use in cancer. Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are some pharmaceutical companies that have CD3 bispecific T cell engagers in development.
Based on current commercial trends, the market for CD3 antibodies appears to be thriving, with various factors favorably influencing the market. Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market. Another factor is the involvement of important pharmaceutical corporations, which boosts the likelihood of success and financial returns associated with top CD3 antibodies. The invention and use of proprietary platforms, which enabled the development of unique CD3 T cell engagers, allowed developers to construct novel antibodies for rare indications, which came with regulatory benefits such as orphan drug designation. Overall, the global CD3 antibody market has enormous potential, much of which is yet relatively untapped.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO CD3 DIRECTED DRUGS
2.1 Overview
2.2 History & Evolution of CD3 Directed Drugs
3. MECHANISM OF ACTION OF CD3 ANTIBODIES
3.1 As Immunosuppressive Therapy
3.2 As Immune Activation Therapy
4. APPLICATION OF CD3 ANTIBODIES BY INDICATION
4.1 Cancer
4.2 Inflammatory & Autoimmune Conditions
5. GLOBAL CD3 ANTIBODIES MARKET & CLINICAL TRIALS OUTLOOK
5.1 Current Market Trends, Developments & Clinical Trials Assessment
5.2 Sales Analysis
5.3 Future Market Opportunities
6. CD3 TARGETING ANTIBODIES MARKET LANDSCAPE BY REGION
6.1 US
6.2 EU
6.3 Canada
6.4 UK
6.5 Japan
7. APPROVED CD3 ANTIBODY DOSAGE, PATENT, PRICE & SALES INSIGHT
7.1 Blincyto – 1st Approved CD3 Antibody
7.2 Kimmtrak – 2nd Approved CD3 Antibody
7.3 Tecvayli – 3rd Approved CD3 Antibody
7.4 Others (6 More CD3 Antibodies)
8. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS OVERVIEW
8.1 By Company
8.2 By Country
8.3 By Indication
8.4 By Phase
8.5 By Patient Segment
9. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
10. MARKETED CD3 ANTIBODIES CLINICAL INSIGHT BY COMPANY & INDICATION
11. GLOBAL CD3 INHIBITORS MARKET DYNAMICS
11.1 Drivers & Opportunities
11.2 Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 Abpro Therapeutics
12.2 Adagene
12.3 Amgen
12.4 Astellas Pharma
12.5 Beijing Mabworks Biotech
12.6 BioAtla
12.7 Genentech
12.8 Genmab
12.9 Harbour BioMed
12.10 Harpoon Therapeutics
12.11 IGM Biosciences
12.12 Immunocore
12.13 Integral Molecular
12.14 ITabMed
12.15 Janssen Research & Development
12.16 Janux Therapeutics
12.17 KeyMed Biosciences
12.18 Light Chain Bioscience
12.19 Linton Pharm
12.20 MacroGenics
12.21 Memorial Sloan-Kettering Cancer Center
12.22 Pfizer
12.23 Qilu Pharmaceutical
12.24 Regeneron Pharmaceuticals
12.25 Roche
12.26 Sichuan Baili Pharmaceutical
12.27 SystImmune
12.28 Takeda
12.29 Xencor
12.30 Zymeworks
Table 7-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 7-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 7-3: Blincyto – Recommended Dose Modifications
Table 7-4: Kimmtrak - Recommended Dosage for Treatment of Unresectable or
Metastatic Uveal Melanoma
Table 7-5: Kimmtrak - Dose Modifications for Adverse Reactions
Table 7-6: Tecvayli - Dosing Schedule
Table 7-7: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 7-8: Tzield - Recommended Dosage and Administration
Table 7-9: Lunsumio - Recommended Dose & Schedule for 21-Day Treatment Cycles
Table 7-10: Lunsumio - Recommendations for Management of Cytokine Release
Syndrome
Table 7-11: Lunsumio - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-12: Lunsumio - Recommended Dosage Modification for Adverse Reactions
Table 7-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 7-14: Columvi - Recommendations for Management of Cytokine Release
Syndrome
Table 7-15: Columvi - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-16: Columvi - Recommended Dosage Modification for Adverse Reactions
Table 7-17: Epkinly - Dosage Schedule
Table 7-18: Epkinly - Recommendations for Management of Cytokine Release
Syndrome
Table 7-19: Epkinly - Recommendations for Management of Immune Effector Cell-
Associated Neurotoxicity Syndrome (ICANS)
Table 7-20: Epkinly - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-21: Talvey - Weekly Dosing Schedule
Table 7-22: Talvey – Biweekly Dosing Schedule
Table 7-23: Talvey - Recommendations for Management of CRS
Table 7-24: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 7-25: Talvey - Recommendations for Management of Neurologic Toxicity
(excluding ICANS)
Table 7-26: Talvey - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-27: Elrexfio - Dosing Schedule
Table 7-28: Elrexfio - Recommendations for Management of CRS
Table 7-29: Elrexfio - Recommended Dosage Modifications for Other Adverse
Reactions
Figure 2-1: TCR-CD3 Structure
Figure 2-2: BiTE – Amgen
Figure 2-3: Development & Evolution of CD3 Targeting Antibodies
Figure 3-1: Bispecific T cell Engaging Antibody
Figure 4-1: Elranatamab Phase III MAGNETISMM-5 Study – Initiation & Completion
Years
Figure 4-2: Elranatamab Phase III MagnetisMM-7 Study – Initiation & Completion
Years
Figure 4-3: Elranatamab Phase III MagnetisMM-6 Study – Initiation & Completion
Years
Figure 4-4: Epcoritamab Phase III EPCORE DLBCL-1 Study – Initiation & Completion
Years
Figure 4-5: Epcoritamab Phase III EPCORE FL-1 Study – Initiation & Completion
Years
Figure 4-6: Epcoritamab Phase III Study – Initiation & Completion Years
Figure 4-7: Talquetamab Phase III MonumenTAL-3 Study – Initiation & Completion
Years
Figure 4-8: Glofitamab Phase III Study – Initiation & Completion Years
Figure 4-9: LINKER-MM3 Phase III Study – Initiation & Completion Years
Figure 4-10: Tzield - Mechanism of Action
Figure 5-1: Global – CD3 Antibodies Sales (US$ Million), 2019 - 2023
Figure 5-2: Global – CD3 Antibodies Sales Shares (US$ Million), H1’2023
Figure 5-3: Global – CD3 Antibodies Sales Shares (%), H1’2023
Figure 5-4: Global – CD3 Antibodies Sales (US$ Million), 2023 - 2028
Figure 6-1: US vs ROW - CD3 Antibodies Market By Region (US$ Million), 2022-2023
Figure 6-2: US vs ROW - CD3 Antibodies Market By Region (%), H1’2023
Figure 6-3: US vs ROW - CD3 Antibodies Market By Region (%), 2022
Figure 6-4: US vs ROW - CD3 Antibodies Market By Region (US$ Million), 2021
Figure 6-5: US vs ROW - CD3 Antibodies Market By Region (%), 2021
Figure 7-1: Blincyto – Approval Years by Region
Figure 7-2: Blincyto – US Patent Acceptance & Expiration Years
Figure 7-3: Blincyto – Europe Patent Expiration Years
Figure 7-4: Blincyto – Treatment Course of MRD-Positive B-cell precursor ALL
Figure 7-5: Blincyto – Duration of Treatment Phase & Resting Phase in Induction &
Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 7-6: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of
MRD-positive B-cell Precursor ALL
Figure 7-7: Blincyto – Recommended Number of Induction & Consolidation
Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 7-8: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle
& Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 7-9: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for
Relapsed B-Cell Precursor ALL
Figure 7-10: Global – Blincyto Sales (US$ Million), 2019-2023
Figure 7-11: US – Blincyto Sales (US$ Million), 2019-2023
Figure 7-12: ROW – Blincyto Sales (US$ Million), 2019-2023
Figure 7-13: Global – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-14: US – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-15: ROW – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-16: Global – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-17: US – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-18: ROW – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-19: Kimmtrak – Approval Years by Region
Figure 7-20: Kimmtrak – Cost Per Unit & Per Vial (US$), October’2023
Figure 7-21: Global – Kimmtrak Sales (US$ Million), 2022-H1’2023
Figure 7-22: Global – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-23: Kimmtrak – Sales by Region (US$ Million), H1’2023
Figure 7-24: US – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-25: EU – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-26: ROW – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-27: Global – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-28: Kimmtrak – Sales by Region (US$ Million), 2022
Figure 7-29: US – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-30: EU – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-31: ROW – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-32: Tecvayli – Approval Years by Region
Figure 7-33: Tecvayli – Patent Acceptance & Expiration Years
Figure 7-34: US – Cost Of 10 mg/ ml Tecvayli Vial (US$), October’2023
Figure 7-35: US - Cost Of 90 mg/mL Vial Tecvayli (US$), October’2023
Figure 7-36: EU - Cost of 1 mg/ml Vial Tecvayli (EUR v/s US$), October’2023
Figure 7-37: EU - Cost of 90 mg/mL Vial Tecvayli (EUR v/s US$), October’2023
Figure 7-38: Tzield – Approval Years by Region
Figure 7-39: Tzield – Cost Of 2 ml Vial (US$), October’2023
Figure 7-40: Tzield – Cost Of 20 ml Vial (US$), October’2023
Figure 7-41: Tzield – Cost Of 28 ml Vial (US$), October’2023
Figure 7-42: Lunsumio – Approval Years by Region
Figure 7-43: US - Cost Of 1 mg/ml Lunsumio Vial (US$), October’2023
Figure 7-44: US - Cost Of 30 mg/30 ml Lunsumio Vial (US$), October’2023
Figure 7-45: EU - Cost of 1 mg/ml Lunsumio Vial (EUR v/s US$), October’2023
Figure 7-46: EU - Cost Of 30 mg/30 ml Lunsumio Vial (EUR v/s US$), October’2023
Figure 7-47: Global – Lunsumio Sales (US$ Million), 2022-2023
Figure 7-48: Regional - Lunsumio Quarterly Sales (US$ Million), H1’2023
Figure 7-49: Regional - Lunsumio Quarterly Sales (US$ Million), H1’2023
Figure 7-50: Lunsumio - Quarterly Sales (US$ Million), Q3-Q4’2022
Figure 7-51: Columvi – Approval Years by Region
Figure 7-52: EU - Cost of 2.5 mg/2.5 mL Columvi Vial (EUR v/s US$), October’2023
Figure 7-53: EU - Cost 10 mg/10 mL Columvi Vial (EUR v/s US$), October’2023
Figure 7-54: Epkinly – Approval Years by Region
Figure 7-55: US - Cost of Epkinly (US$), October’2023
Figure 7-56: EU - Cost of Epkinly (EUR v/s US$), October’2023
Figure 7-57: Global – Epkinly Sales (US$ Million), 2023
Figure 7-58: Global – Quarterly Epkinly Sales (US$ Million), 2023
Figure 7-59: Talvey – Approval Years by Region
Figure 7-60: Talquetamab – FDA & EMA Designation Years
Figure 7-61: Talvey – Patent Acceptance & Expiration Years
Figure 7-62: Elrexfio – Approval Years by Region
Figure 7-63: Elranatamab – FDA & EMA Designation Years
Figure 8-1: Global – CD3 Antibodies Clinical Pipeline by Company (Numbers), 2023
Till 2028
Figure 8-2: Global – CD3 Antibodies Clinical Pipeline by Country (Numbers), 2023
Till 2028
Figure 8-3: Global – CD3 Antibodies Clinical Pipeline by Indication (Numbers), 2023
Till 2028
Figure 8-4: Global – CD3 Antibodies Clinical Pipeline by Phase (Numbers), 2023 Till
2028
Figure 8-5: Global – CD3 Antibodies Clinical Pipeline by Patient Segment (Numbers),
2023 TILL 2028
2. INTRODUCTION TO CD3 DIRECTED DRUGS
2.1 Overview
2.2 History & Evolution of CD3 Directed Drugs
3. MECHANISM OF ACTION OF CD3 ANTIBODIES
3.1 As Immunosuppressive Therapy
3.2 As Immune Activation Therapy
4. APPLICATION OF CD3 ANTIBODIES BY INDICATION
4.1 Cancer
4.2 Inflammatory & Autoimmune Conditions
5. GLOBAL CD3 ANTIBODIES MARKET & CLINICAL TRIALS OUTLOOK
5.1 Current Market Trends, Developments & Clinical Trials Assessment
5.2 Sales Analysis
5.3 Future Market Opportunities
6. CD3 TARGETING ANTIBODIES MARKET LANDSCAPE BY REGION
6.1 US
6.2 EU
6.3 Canada
6.4 UK
6.5 Japan
7. APPROVED CD3 ANTIBODY DOSAGE, PATENT, PRICE & SALES INSIGHT
7.1 Blincyto – 1st Approved CD3 Antibody
7.2 Kimmtrak – 2nd Approved CD3 Antibody
7.3 Tecvayli – 3rd Approved CD3 Antibody
7.4 Others (6 More CD3 Antibodies)
8. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS OVERVIEW
8.1 By Company
8.2 By Country
8.3 By Indication
8.4 By Phase
8.5 By Patient Segment
9. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
10. MARKETED CD3 ANTIBODIES CLINICAL INSIGHT BY COMPANY & INDICATION
11. GLOBAL CD3 INHIBITORS MARKET DYNAMICS
11.1 Drivers & Opportunities
11.2 Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 Abpro Therapeutics
12.2 Adagene
12.3 Amgen
12.4 Astellas Pharma
12.5 Beijing Mabworks Biotech
12.6 BioAtla
12.7 Genentech
12.8 Genmab
12.9 Harbour BioMed
12.10 Harpoon Therapeutics
12.11 IGM Biosciences
12.12 Immunocore
12.13 Integral Molecular
12.14 ITabMed
12.15 Janssen Research & Development
12.16 Janux Therapeutics
12.17 KeyMed Biosciences
12.18 Light Chain Bioscience
12.19 Linton Pharm
12.20 MacroGenics
12.21 Memorial Sloan-Kettering Cancer Center
12.22 Pfizer
12.23 Qilu Pharmaceutical
12.24 Regeneron Pharmaceuticals
12.25 Roche
12.26 Sichuan Baili Pharmaceutical
12.27 SystImmune
12.28 Takeda
12.29 Xencor
12.30 Zymeworks
Table 7-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 7-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 7-3: Blincyto – Recommended Dose Modifications
Table 7-4: Kimmtrak - Recommended Dosage for Treatment of Unresectable or
Metastatic Uveal Melanoma
Table 7-5: Kimmtrak - Dose Modifications for Adverse Reactions
Table 7-6: Tecvayli - Dosing Schedule
Table 7-7: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 7-8: Tzield - Recommended Dosage and Administration
Table 7-9: Lunsumio - Recommended Dose & Schedule for 21-Day Treatment Cycles
Table 7-10: Lunsumio - Recommendations for Management of Cytokine Release
Syndrome
Table 7-11: Lunsumio - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-12: Lunsumio - Recommended Dosage Modification for Adverse Reactions
Table 7-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 7-14: Columvi - Recommendations for Management of Cytokine Release
Syndrome
Table 7-15: Columvi - Recommendations for Management of Neurologic Toxicity
(Including ICANS)
Table 7-16: Columvi - Recommended Dosage Modification for Adverse Reactions
Table 7-17: Epkinly - Dosage Schedule
Table 7-18: Epkinly - Recommendations for Management of Cytokine Release
Syndrome
Table 7-19: Epkinly - Recommendations for Management of Immune Effector Cell-
Associated Neurotoxicity Syndrome (ICANS)
Table 7-20: Epkinly - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-21: Talvey - Weekly Dosing Schedule
Table 7-22: Talvey – Biweekly Dosing Schedule
Table 7-23: Talvey - Recommendations for Management of CRS
Table 7-24: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 7-25: Talvey - Recommendations for Management of Neurologic Toxicity
(excluding ICANS)
Table 7-26: Talvey - Recommended Dosage Modifications for Other Adverse
Reactions
Table 7-27: Elrexfio - Dosing Schedule
Table 7-28: Elrexfio - Recommendations for Management of CRS
Table 7-29: Elrexfio - Recommended Dosage Modifications for Other Adverse
Reactions
Figure 2-1: TCR-CD3 Structure
Figure 2-2: BiTE – Amgen
Figure 2-3: Development & Evolution of CD3 Targeting Antibodies
Figure 3-1: Bispecific T cell Engaging Antibody
Figure 4-1: Elranatamab Phase III MAGNETISMM-5 Study – Initiation & Completion
Years
Figure 4-2: Elranatamab Phase III MagnetisMM-7 Study – Initiation & Completion
Years
Figure 4-3: Elranatamab Phase III MagnetisMM-6 Study – Initiation & Completion
Years
Figure 4-4: Epcoritamab Phase III EPCORE DLBCL-1 Study – Initiation & Completion
Years
Figure 4-5: Epcoritamab Phase III EPCORE FL-1 Study – Initiation & Completion
Years
Figure 4-6: Epcoritamab Phase III Study – Initiation & Completion Years
Figure 4-7: Talquetamab Phase III MonumenTAL-3 Study – Initiation & Completion
Years
Figure 4-8: Glofitamab Phase III Study – Initiation & Completion Years
Figure 4-9: LINKER-MM3 Phase III Study – Initiation & Completion Years
Figure 4-10: Tzield - Mechanism of Action
Figure 5-1: Global – CD3 Antibodies Sales (US$ Million), 2019 - 2023
Figure 5-2: Global – CD3 Antibodies Sales Shares (US$ Million), H1’2023
Figure 5-3: Global – CD3 Antibodies Sales Shares (%), H1’2023
Figure 5-4: Global – CD3 Antibodies Sales (US$ Million), 2023 - 2028
Figure 6-1: US vs ROW - CD3 Antibodies Market By Region (US$ Million), 2022-2023
Figure 6-2: US vs ROW - CD3 Antibodies Market By Region (%), H1’2023
Figure 6-3: US vs ROW - CD3 Antibodies Market By Region (%), 2022
Figure 6-4: US vs ROW - CD3 Antibodies Market By Region (US$ Million), 2021
Figure 6-5: US vs ROW - CD3 Antibodies Market By Region (%), 2021
Figure 7-1: Blincyto – Approval Years by Region
Figure 7-2: Blincyto – US Patent Acceptance & Expiration Years
Figure 7-3: Blincyto – Europe Patent Expiration Years
Figure 7-4: Blincyto – Treatment Course of MRD-Positive B-cell precursor ALL
Figure 7-5: Blincyto – Duration of Treatment Phase & Resting Phase in Induction &
Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 7-6: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of
MRD-positive B-cell Precursor ALL
Figure 7-7: Blincyto – Recommended Number of Induction & Consolidation
Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 7-8: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle
& Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 7-9: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for
Relapsed B-Cell Precursor ALL
Figure 7-10: Global – Blincyto Sales (US$ Million), 2019-2023
Figure 7-11: US – Blincyto Sales (US$ Million), 2019-2023
Figure 7-12: ROW – Blincyto Sales (US$ Million), 2019-2023
Figure 7-13: Global – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-14: US – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-15: ROW – Quarterly Blincyto Sales (US$ Million), H1’2023
Figure 7-16: Global – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-17: US – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-18: ROW – Quarterly Blincyto Sales (US$ Million), 2022
Figure 7-19: Kimmtrak – Approval Years by Region
Figure 7-20: Kimmtrak – Cost Per Unit & Per Vial (US$), October’2023
Figure 7-21: Global – Kimmtrak Sales (US$ Million), 2022-H1’2023
Figure 7-22: Global – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-23: Kimmtrak – Sales by Region (US$ Million), H1’2023
Figure 7-24: US – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-25: EU – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-26: ROW – Quarterly Kimmtrak Sales (US$ Million), H1’2023
Figure 7-27: Global – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-28: Kimmtrak – Sales by Region (US$ Million), 2022
Figure 7-29: US – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-30: EU – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-31: ROW – Quarterly Kimmtrak Sales (US$ Million), 2022
Figure 7-32: Tecvayli – Approval Years by Region
Figure 7-33: Tecvayli – Patent Acceptance & Expiration Years
Figure 7-34: US – Cost Of 10 mg/ ml Tecvayli Vial (US$), October’2023
Figure 7-35: US - Cost Of 90 mg/mL Vial Tecvayli (US$), October’2023
Figure 7-36: EU - Cost of 1 mg/ml Vial Tecvayli (EUR v/s US$), October’2023
Figure 7-37: EU - Cost of 90 mg/mL Vial Tecvayli (EUR v/s US$), October’2023
Figure 7-38: Tzield – Approval Years by Region
Figure 7-39: Tzield – Cost Of 2 ml Vial (US$), October’2023
Figure 7-40: Tzield – Cost Of 20 ml Vial (US$), October’2023
Figure 7-41: Tzield – Cost Of 28 ml Vial (US$), October’2023
Figure 7-42: Lunsumio – Approval Years by Region
Figure 7-43: US - Cost Of 1 mg/ml Lunsumio Vial (US$), October’2023
Figure 7-44: US - Cost Of 30 mg/30 ml Lunsumio Vial (US$), October’2023
Figure 7-45: EU - Cost of 1 mg/ml Lunsumio Vial (EUR v/s US$), October’2023
Figure 7-46: EU - Cost Of 30 mg/30 ml Lunsumio Vial (EUR v/s US$), October’2023
Figure 7-47: Global – Lunsumio Sales (US$ Million), 2022-2023
Figure 7-48: Regional - Lunsumio Quarterly Sales (US$ Million), H1’2023
Figure 7-49: Regional - Lunsumio Quarterly Sales (US$ Million), H1’2023
Figure 7-50: Lunsumio - Quarterly Sales (US$ Million), Q3-Q4’2022
Figure 7-51: Columvi – Approval Years by Region
Figure 7-52: EU - Cost of 2.5 mg/2.5 mL Columvi Vial (EUR v/s US$), October’2023
Figure 7-53: EU - Cost 10 mg/10 mL Columvi Vial (EUR v/s US$), October’2023
Figure 7-54: Epkinly – Approval Years by Region
Figure 7-55: US - Cost of Epkinly (US$), October’2023
Figure 7-56: EU - Cost of Epkinly (EUR v/s US$), October’2023
Figure 7-57: Global – Epkinly Sales (US$ Million), 2023
Figure 7-58: Global – Quarterly Epkinly Sales (US$ Million), 2023
Figure 7-59: Talvey – Approval Years by Region
Figure 7-60: Talquetamab – FDA & EMA Designation Years
Figure 7-61: Talvey – Patent Acceptance & Expiration Years
Figure 7-62: Elrexfio – Approval Years by Region
Figure 7-63: Elranatamab – FDA & EMA Designation Years
Figure 8-1: Global – CD3 Antibodies Clinical Pipeline by Company (Numbers), 2023
Till 2028
Figure 8-2: Global – CD3 Antibodies Clinical Pipeline by Country (Numbers), 2023
Till 2028
Figure 8-3: Global – CD3 Antibodies Clinical Pipeline by Indication (Numbers), 2023
Till 2028
Figure 8-4: Global – CD3 Antibodies Clinical Pipeline by Phase (Numbers), 2023 Till
2028
Figure 8-5: Global – CD3 Antibodies Clinical Pipeline by Patient Segment (Numbers),
2023 TILL 2028
